A Phase 3 trial presented Sunday at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul found that adding the experimental oral drug zipalertinib to standard chemotherapy roughly doubled how long previously untreated patients with a specific, biomarker-defined form of advanced non-small cell lung cancer (NSCLC) went before their disease worsened, compared with chemotherapy alone. The data matter for investors because zipalertinib already has one FDA decision pending for a different use in the same disease, and because it would compete in a market where a rival drug already holds approval.

What the Trial Found

The trial, called REZILIENT3 (NCT05973773), is an international, randomized, open-label Phase 3 study. It enrolled 279 patients with advanced NSCLC whose tumors carry EGFR exon 20 insertion mutations, a specific genetic subtype, who had not yet received treatment for advanced disease. Patients were randomly assigned, with 140 receiving zipalertinib (100 mg twice daily) plus platinum-pemetrexed chemotherapy and 139 receiving chemotherapy alone; patients on chemotherapy alone could switch to zipalertinib after their disease progressed. Patients with small, untreated, symptom-free brain metastases were allowed to enroll.

Median progression-free survival, assessed by blinded independent central review, was 14.5 months with the zipalertinib combination versus 8.5 months with chemotherapy alone, reflecting a 50% reduction in the risk of disease progression or death (hazard ratio 0.50; 95% CI, 0.34-0.73; P=0.00015). The benefit held up across patient subgroups, including those with brain metastases (HR 0.38). Objective response rate, the share of patients whose tumors measurably shrank, was 65.0% with the combination versus 40.3% with chemotherapy alone (P<0.0001), and median duration of response, how long those responses lasted, was 14.2 months versus 9.9 months. An early look at overall survival, based on only 30% of the data maturing so far, showed a hazard ratio of 0.72 (95% CI, 0.42-1.23), a trend that has not yet reached statistical significance since the confidence interval crosses 1.0, and one that investigators say will need more follow-up to confirm.

Who Is Actually Behind Zipalertinib

The IASLC’s release, consistent with its role as a neutral scientific association reporting conference data, does not name the companies developing zipalertinib or mention any stock ticker. Zipalertinib is being co-developed by Taiho Pharmaceutical Co., Ltd., a Tokyo-based, wholly owned subsidiary of publicly traded Otsuka Holdings Co., Ltd. (Tokyo Stock Exchange: 4578), and Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company. Under the companies’ collaboration agreement, Cullinan is entitled to 50% of any future pretax U.S. profits from zipalertinib. Zai Lab Limited (Nasdaq: ZLAB; Hong Kong Stock Exchange: 9688) separately holds an exclusive license to develop and commercialize zipalertinib in Greater China. None of this corporate or ticker information appeared in the IASLC release; it was independently verified from company securities filings and investor materials.

Where This Fits in the Regulatory Picture

It is important not to conflate this first-line data with zipalertinib’s existing regulatory status. The FDA has already accepted a separate New Drug Application for zipalertinib, but that filing covers a different, later-line use: patients whose EGFR exon 20 insertion-positive NSCLC has progressed after platinum-based chemotherapy, based on Phase 2b data from the REZILIENT1 trial. That application carries a target FDA action date of February 27, 2027, and remains under review, not approved. The REZILIENT3 first-line data presented in Seoul comes from a separate, ongoing trial, and Cullinan and Taiho have not said whether or when they will seek an additional, first-line approval based on it.

A Crowded, Partly Approved Field

Zipalertinib would not be entering an empty market. Amivantamab, marketed as Rybrevant by Johnson & Johnson’s Janssen unit, already holds full FDA approval, granted in 2024, for first-line use alongside chemotherapy in the same EGFR exon 20 insertion-positive NSCLC population, based on the separate Phase 3 PAPILLON trial. In that trial, amivantamab plus chemotherapy produced a median progression-free survival of 11.4 months versus 6.7 months for chemotherapy alone (hazard ratio 0.40; 95% CI, 0.30-0.53). Those figures are not directly comparable to REZILIENT3’s results, since the two studies enrolled different patient populations at different times and were never run head-to-head against each other; any comparison between the trials is suggestive at best, not proof that either drug outperforms the other.

Safety

The combination’s side-effect profile was described as generally consistent with the known safety profiles of the individual drugs. Grade 3 or higher adverse events occurred in 87.1% of patients on the zipalertinib combination versus 54.4% on chemotherapy alone, driven mainly by manageable blood-related side effects. Higher-grade skin- and gut-related toxicities specifically linked to EGFR-targeting drugs, including rash (10.7%) and diarrhea (1.4%), occurred only in the combination arm. Investigators reported no new safety signals.

What Wasn’t Disclosed

The release did not provide a timeline for when Cullinan and Taiho might submit REZILIENT3 data to regulators for a first-line approval, nor how mature the final overall survival analysis will need to be before results are reported. Follow-up on REZILIENT3 is ongoing to further characterize overall survival and other exploratory endpoints. This article covers clinical trial data and is not medical or investment advice.

Sources

International Association for the Study of Lung Cancer: Zipalertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Positive NSCLC, PRNewswire, September 14, 2026. Primary source release.

Cullinan Therapeutics: U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib, cited for zipalertinib’s co-development structure, Cullinan’s economics, and the separate, pending second-line NDA and PDUFA date, none of which appeared in the IASLC release.

Johnson & Johnson / Janssen: RYBREVANT (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With NSCLC With EGFR Exon 20 Insertion Mutations, cited for competitive-landscape context on the already-approved rival therapy amivantamab and its Phase 3 PAPILLON trial data.

Zai Lab Ltd. Form 10-K (SEC EDGAR), cited for Zai Lab’s exclusive Greater China license to zipalertinib.

Editorial Disclosure

This article reports on clinical trial data presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) regarding zipalertinib. Securities and corporate structures discussed: Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Otsuka Holdings Co., Ltd. (Tokyo Stock Exchange: 4578, via its wholly owned subsidiary Taiho Pharmaceutical Co., Ltd.), and Zai Lab Limited (Nasdaq: ZLAB; Hong Kong Stock Exchange: 9688). BioTech Stocks Daily has not received, nor will it accept, any compensation—direct or indirect—from Cullinan Therapeutics, Taiho Pharmaceutical, Otsuka Holdings, Zai Lab, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Statements regarding the timing of future regulatory submissions, eventual first-line approval prospects, target action dates (such as the February 27, 2027 PDUFA date for second-line use), potential commercial competition, and survival endpoint maturity are forward-looking statements. They involve substantial risks, regulatory uncertainties, and scientific variables; actual clinical outcomes, development timelines, and commercial approvals may differ materially. Clinical-stage biotechnology investments carry an extreme degree of financial risk. Drug development is subject to high rates of clinical failure, regulatory rejection, and market competition, which can result in the total loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full Terms & Disclaimers Page